Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 17, 2021
Deals
Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates
Under a three-year deal, which builds on a 2020 agreement to develop therapies for coronaviruses, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) gained exclusive rights to collaborate with Vir
BioCentury | Jul 29, 2020
Emerging Company Profile
Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant
Bright Peak brings a chemical synthesis approach to the modified IL-2 arena
BioCentury | Sep 26, 2019
Clinical News
Nektar falls on TNBC data for doublet, but considering moving ahead with a triple combo
BioCentury | Jul 18, 2019
Emerging Company Profile
Neoleukin emerges with a de novo approach to improving biologics
Why Neoleukin is making biologics from scratch rather than fine-tuning existing ones
Items per page:
1 - 5 of 5